Novo Nordisk subsupplier reinitiates Wegovy production

According to Novo Nordisk, a contract manufacturer filling the syringes for Novo’s obesity drug Wegovy has once again started its commercial production.

Photo: Pool/Reuters/Ritzau Scanpix

In connection with Novo Nordisk’s first quarterly report Friday morning, the company has announced that the contract manufacturer in charge of filling Wegovy doses, an obesity treatment currently available in the US, has reinitiated its commercial production.

The subsupplier had run into issues in the past, which strained the overall production plans for Wegovy.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Rumored GN purchase unlikely but not impossible, say analysts

A low value assessment, a high structural value, and no dominant shareholders make GN Group a reasonable investment case for international private equity firms and industrial players. But just how likely is it? Analysts reveal their best bets for what a GN acquisition could look like.

New CFO wants to shake things up at WSA

A mere month into her new job, Marianne Wiinholt, WS Audiology’s fifth chief financial officer since the firm was established through a merger in 2019, is heralding great structural changes.

Further reading

Related articles

Latest news

See all jobs